Skip to main content
Ovarian Cancer
In Women with Relapsed Ovarian Cancer and BRCA Mutation, Olaparib Extends Survival by >1 Year
Read More
Ovarian Cancer
Patients with Newly Diagnosed Stage III or IV Ovarian Cancer and Atezolizumab
Read More
Ovarian Cancer
Subsequent Chemotherapy Following Olaparib Maintenance Therapy in BRCA1/2 Mutated Platinum-Sensitive Recurrent Epithelial Ovarian Cancer
Read More
Ovarian Cancer
Treatment Strategies and Survival in Women with Malignant Ovarian Germ Cell Tumors
Read More
Ovarian Cancer
Deleterious BRCA Mutations More Likely on Long-Term Responders to Rucaparib
Read More
Ovarian Cancer
In Patients with Ovarian Cancer and Non-BRCA HRR Gene Mutations, Promising Results Seen with Maintenance Rucaparib
Read More
Ovarian Cancer
Maintenance Therapy with Olaparib plus Bevacizumab in Newly Diagnosed Advanced High‐Grade Ovarian Carcinoma
Read More
Ovarian Cancer
Phase 3 ARIEL3 Study: Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer and Timing of Adverse Events
Read More
Ovarian Cancer, PARP Inhibitors
Real-World, Multinational ‘RESPONSE’ to Standard-of-Care Practices with PARP Inhibitors in Patients with Advanced Ovarian Cancer
Read More
Ovarian Cancer
In Patients with Advanced Ovarian Cancer, Olaparib/Bevacizumab as First-Line Maintenance Reduced the Risk of Progression or Death
Read More
Page 2 of 3
Results 11 - 20 of 27